| Yazarlar (8) |
Selin Genc
|
|
Bahri Evren
|
|
Onur Selcuk Yigit
|
Arş. Gör. İbrahim Baki ŞAHİN
Kırşehir Ahi Evran Üniversitesi, Türkiye |
|
Ramazan Dayanan
|
|
Aleksandra Klisic
|
|
Ayse Erturk
|
|
Filiz Mercantepe
|
| Özet |
| : The antidiabetic effect of SGLT2 inhibitors (SGLT2-is) is based on their ability to increase glucose excretion through urine by inhibiting the kidney-resident SGLT2 protein. Euglycemic diabetic ketoacidosis (EuDKA) is an uncommon but potentially life-threatening adverse effect of these medications, which are notable for their antidiabetic, cardiovascular, and renal protective properties. This study aimed to clarify the impact of SGLT2-is on demographic, clinical, and biochemical characteristics in patients with DKA. : A total of 51 individuals with a diagnosis of DKA were included in the trial; 19 of these patients were treated with SGLT2-is, while 32 were not. Patients diagnosed with DKA and treated with SGLT2-is were compared to those not treated with the medication in terms of clinical, biochemical, and laboratory characteristics. : The age of patients utilizing SGLT2-is was statistically considerably greater than that of non-users ( < 0.001). EuDKA was exclusively noted in the SGLT2-is cohort ( = 0.005). Urinary tract infections, vulvovaginitis, and genitourinary infections were substantially more prevalent among SGLT2-i users compared with non-users among both women and the overall patient group ( = 0.036, = 0.001, = 0.005, = 0.003, respectively). Plasma glucose concentrations were significantly higher in SGLT2-i non-users ( = 0.006). Chloride (Cl) concentrations were elevated among SGLT2-i users ( = 0.036). : The study findings indicate that SGLT2 inhibitors may substantially influence age, serum chloride, EuDKA, and the occurrence of genitourinary infections in individuals with DKA. |
| Anahtar Kelimeler |
| diabetic ketoacidosis (DKA) | euglycemic diabetic ketoacidosis (euDKA) | genitourinary infection (GUI) | latent autoimmune diabetes in adults (LADA) | sodium-glucose co-transporter-2 inhibitor (SGLT2-i) | type 1 diabetes mellitus (T1DM) |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | ESCI dergilerinde yayımlanan tam makale |
| Dergi Adı | PHARMACEUTICALS |
| Makale Dili | İngilizce |
| Basım Tarihi | 11-2024 |
| Cilt No | 17 |
| Sayı | 11 |
| Doi Numarası | 10.3390/ph17111553 |
| Atıf Sayıları | |
| WoS | 1 |
